What is Adcendo?
Adcendo is dedicated to advancing targeted cancer therapies through its expertise in antibody-drug conjugate (ADC) development. The company leverages a multidisciplinary approach, integrating biology, chemistry, and clinical development to address critical unmet needs in oncology. By focusing on precision medicine and innovative drug design, Adcendo aims to deliver more effective and targeted treatments for patients. Its strategic collaborations with scientific and industry partners further bolster its research and development pipeline, positioning it as a key player in the evolving landscape of cancer therapeutics.
How much funding has Adcendo raised?
Adcendo has raised a total of $316M across 3 funding rounds:
Series A
$106M
Series B
$135M
Series C
$75M
Series A (2024): $106M with participation from Gilde Healthcare, Novo Holdings, and Pontifax
Series B (2024): $135M led by TCG Crossover, Logos Capital Partners Sa rl, and Novo Holdings
Series C (2026): $75M supported by Vida Ventures, RA Capital Management, Logos Capital Partners Sa rl, Bpifrance, Jeito, OrbiMed, Venrock, Glide Healthcare Pvt, and Danish Export and Investment Fund
Key Investors in Adcendo
Vida Ventures
Vida Ventures is a next-generation life sciences investment firm founded by scientists, physicians, entrepreneurs and investors who are passionate about building and funding breakthroughs in biomedicine. Together they have created a bold investment group bound together by a simple word - life. Its mission is to bring science to life and advance transformative biomedical innovations that have the potential to make a meaningful difference for patients. Vida has a bicoastal presence and currently has approximately $1.7 billion under management.
RA Capital Management
RA Capital Management is a multi-stage investment manager focused on evidence-based investing in public and private healthcare and life science companies, including those developing drugs, medical devices, diagnostics, and research tools. The company also has a growing interest in climate and sustainability technologies. RA Capital aims to partner with innovators to bring ideas from the lab to the clinic, ultimately improving patient lives. Their internal think tank, TechAtlas, analyzes scientific and clinical data to support their investment strategies.
Logos Capital Partners Sa rl
Logos Capital Partners Sa rl is a company that operates in the Finance industry. It employs 20to49 people and has 10Mto25M of revenue. The company is headquartered in Cap, Luxembourg.
What's next for Adcendo?
With substantial backing from prominent life sciences investors, Adcendo is poised for accelerated growth and the advancement of its therapeutic pipeline. The recent major strategic investment signals a critical phase for the company, likely enabling the progression of its ADC candidates through clinical trials and towards potential commercialization. This significant capital infusion will support ongoing research, expand its operational capacity, and reinforce its market position in the competitive biotechnology sector. The company's focus on precision medicine and targeted therapies aligns with current trends in oncology, suggesting a strategic path toward addressing complex cancer indications.
See full Adcendo company page
